Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiological trends of non-small cell lung cancer and systemic treatment rates as part of initial therapeutic strategy from 2016 to 2020 in Greece: results of the epidemiological part of INFINITY study.

BMC cancer·2026
Same author

The antibiotic-immunotherapy interaction in NSCLC: a systematic review and meta-analysis of 54,250 patients across three outcomes.

Cancer treatment reviews·2026
Same author

Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Dermatologic adverse events associated with amivantamab: A multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of breast cancer.

Breast cancer research : BCR·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Sep 11, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer.

Chara Papadaki1, Maria Mortoglou1, Aristeidis E Boukouris1,2

  • 1Laboratory of Translational Oncology, School of Medicine, University of Crete, 71500 Heraklion, Greece.

Cancers
|August 14, 2025
PubMed
Summary
This summary is machine-generated.

Researchers identified six microRNAs (miRNAs) suppressed in non-small cell lung cancer (NSCLC) that can predict response to cisplatin chemotherapy. This discovery offers potential biomarkers for personalized treatment strategies in NSCLC patients.

Keywords:
bioinformaticschemoresistancecisplatinmiRNAsnon-small cell lung cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

Related Experiment Videos

Last Updated: Sep 11, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background:

  • Cisplatin chemotherapy effectiveness in non-small cell lung cancer (NSCLC) can be compromised by impaired DNA damage repair mechanisms.
  • MicroRNAs (miRNAs) are key regulators of DNA damage repair and are being investigated as predictive biomarkers for platinum-based chemotherapy response in NSCLC.

Purpose of the Study:

  • To identify differentially expressed miRNAs between responders and non-responders to platinum-based chemotherapy in NSCLC using a bioinformatics approach.
  • To validate the expression of identified miRNAs in clinical tissue samples from NSCLC patients.

Main Methods:

  • Retrieved and analyzed two miRNA microarray expression datasets from the Gene Expression Omnibus (GEO) repository (N=69 NSCLC patients).
  • Utilized Linear Models for Microarray Analysis (Limma) package for differential expression analysis to identify differentially expressed miRNAs.
  • Validated miRNA expression using quantitative real-time PCR (qRT-PCR) on clinical tumor and matched normal tissues (N=20).

Main Results:

  • Identified 112 differentially expressed miRNAs between responders and non-responders; a meta-analysis revealed 24 consistently altered miRNAs.
  • Survival analysis indicated 22 miRNAs significantly associated with NSCLC prognosis.
  • A six-miRNA signature (miR-26a, miR-29c, miR-34a, miR-30e-5p, miR-30e-3p, miR-497) was identified, downregulated in non-responders and linked to DNA damage repair pathways (p53, Hippo, PI3K, TGF-β).

Conclusions:

  • A signature of six suppressed miRNAs in NSCLC was identified.
  • This six-miRNA signature shows potential as a predictive biomarker for cisplatin response in NSCLC patients.
  • The findings suggest miRNAs play a crucial role in DNA damage repair and chemotherapy response in NSCLC.